Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HMR's Allegra has 3.3% of new antihistamine Rxs, $1.9 mil. sales in second month on market -- Scott Levin.

Executive Summary

HOECHST MARION ROUSSEL ALLEGRA CAPTURES 3.3% OF NEW PRESCRIPTIONS dispensed in September for oral solid antihistamines, according to Scott-Levin's Source Prescription Audit. The 48,000 new prescriptions helped to generate $1.9 mil. in retail pharmacy sales for Allegra. Allegra, a metabolite of HMR's Seldane, was launched in August ("The Pink Sheet" Aug. 26, T&G-2).

Latest Headlines
See All
UsernamePublicRestriction

Register

PS029069

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel